主持国家自然科学青年基金1项、省自然科学基金1项，武汉市知识创新曙光计划项目1项、中国药学会医院药学专委会优秀人才项目1项；参与国家重点研发计划项目1项、国家自然科学基金面上项目2项、湖北省中医药科研重点项目1项、多项药物临床试验等课题。以第一或通讯作者发表论文30余篇，其中SCI收录25篇，参与撰写并发布共识2部，授权发明专利2项。荣获湖北省科技进步一等奖1项（4/14）、《中国医院药学杂志》优秀论文一等奖。研发的医院新制剂“益肾排毒丸”成功获批湖北省医疗机构制剂注册批准文号（鄂药制字Z20181033），并获医院新技术新业务成果奖三等奖。BMC系列杂志、《中草药》、《药物评价研究》审稿人。
主持科研项目：
中国药学会医院药学专委会优秀人才项目，基于真实世界医疗大数据的抗银屑病生物制剂不良反应特征分析及其预测模型研究，2023/09-2025/09，在研，主持
武汉市知识创新专项曙光计划项目，基于真实世界医疗大数据的PARP抑制剂不良事件信号挖掘及其预测模型构建，2023/06-2025/06，在研，主持
3.国家自然科学基金，益肾排毒方抑制miR-21促进足细胞自噬治疗糖尿病肾病的作用机制研究，2022/01-2024/12，在研，主持
4.湖北省自然科学基金，当归多糖调节肝星状细胞活化增殖防治酒精性肝纤维化的作用及机制研究，2017/08-2019/07，已结题，主持
5.湖北省生物靶向重点实验室，当归多糖靶向肝脏Nrf2-NF-κB通路抗APAP诱导的急性肝损伤的作用机制，2017/06-2019/06，已结题，主持
参与科研项目：
6.国家自然科学基金，Dectin-1介导的香菇多糖体内吸收代谢机制研究，2020/01-2023/12，已结题，参与
7.湖北省卫健委中医药科研重点项目，中药复方多糖胶囊剂的研发及其改善糖脂代谢的机制研究，2021/01-2022/12，已结题，参与
8.国家重点研发计划项目子课题，典型病种精准用药模型的集成、推广与优化，2017/07-2020/12，已结题，参与
9.国家自然科学基金，香菇多糖的抗肿瘤构效关系及诱导肿瘤细胞凋亡的分子机制研究，2014/01-2017/12，已结题，参与
论文代表作（第一作者或通讯作者）
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis. Pharmaceuticals, 2024, 17(8):1028.
A Real-World Disproportionality Analysis of Rucaparib: Post-marketing Pharmacovigilance Data. BMC Cancer, 2023, 23(1):745.
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment. Drug Safety, 2023, 46(9):881-895.
Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. International Immunopharmacology, 2023, 122:110543.
Adverse events with risankizumab in the real world: post-marketing pharmacovigilance assessment of the FDA adverse event reporting system.Frontiers in Immunology, 2023, 14:1169735.
Cardiac Adverse Events Associated with Quetiapine: Disproportionality Analysis of FDA Adverse Event Reporting System. CNS Neuroscience & Therapeutics, 2023, 29(9):2705-2716.
Cost-effectiveness of Sintilimab Plus Chemotherapy versus Chemotherapy Alone as First-Line Treatment of Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma.Frontiers in Immunology, 2023, 14:1092385.
Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. International Immunopharmacology, 2023, 114:109589.
Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Medicine, 2023, 12(3): 3365-3375.
Gastrointestinal Adverse Events Associated with Semaglutide: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System.Frontiers in Public Health, 2022, 10:996179.
Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer. Cancer Control, 2022, 29:1-10.
Cost-effectiveness of Osimertinib versus Standard EGFR-TKI as First-line Treatment for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer in China.Frontiers in Pharmacology, 2022, 13:920479.
Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on FAERS database.Frontiers in Pharmacology, 2022, 13:990241.
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.Frontiers in Pharmacology, 2022, 13:818579.
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System. Clinical Epidemiology, 2022, 14:789-802.
Post-marketing Safety Concerns with Secukinumab: A Disproportionality Analysis of FDA Adverse Event Reporting System. Frontiers in Pharmacology, 2022, 13:862508.
Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China. Frontiers in Oncology, 2022, 12:851522.
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opinion on Drug Safety, 2022, 21(4): 563-572.
Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management. Current Medical Science, 2022, 42(3):530-537.
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers in Oncology, 2021, 11:790373.
Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice. Frontiers in Pharmacology, 2021, 12:781856.
Protective Effect of Yi Shen Pai Du Formula against Diabetic Kidney Injury via Inhibition of Oxidative Stress, Inflammation, and Epithelial-to-Mesenchymal Transition in db/db Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021:7958021.
Association of Myocardial Enzyme Abnormality with Clinical Outcomes of Patients with COVID-19: A Retrospective Study. Disease Markers. 2021, 2021:3440714.
Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China. Cancer Management and Research. 2021, 13:8297-8306.
Apoptosis induction activity of polysaccharide fromLentinus edodesin H22-bearing mice through ROS-mediated mitochondrial pathway and inhibition of tubulin polymerization. Food & Nutrition Research, 2020, 64, 1-13.
基于FAERS对帕博利珠单抗和纳武利尤单抗不良事件的分析.中国药师, 2022, 25(8): 1384-1390.
基于FAERS数据库的芳香化酶抑制剂不良事件信号挖掘研究.中国现代应用药学, 2022, 40(2): 224-231.
培美曲塞联合贝伐珠单抗维持治疗晚期非鳞状非小细胞肺癌成本-效果分析.中国药业, 2022, 31(10): 106-111.
聚乙二醇脂质体阿霉素联合化疗方案治疗复发性卵巢癌的成本-效果分析.中国医院药学杂志，2021, 41(22):2322-2327.
益肾排毒丸调节AMPK/ACC信号通路对db/db小鼠肝损伤的保护作用研究.中国医院药学杂志，2021,41(4):360-366.
药食同源植物多糖治疗溃疡性结肠炎的药理作用及机制研究进展.药物评价研究，2021,44(3):644-651.
益肾排毒丸中有效成分含量测定及指纹图谱研究.药物评价研究, 2019, 42(4): 658-662.
益肾排毒丸的稳定性研究.中国医药导报, 2019, 16(13): 29-32.
益肾排毒丸的薄层鉴别及急性毒性试验.中国药师, 2019, 22(8): 1523-1526.
香菇多糖抑制Akt通路和微管蛋白聚合诱导肿瘤细胞凋亡的分子机制，中国医院药学杂志，2016, 36(23):2046-2051.
联系方式：027-85726073 E-mail: qilinzhang88@163.com
通讯地址：红足1世66814同济医学院附属协和医院邮政编码430022
